Veru Inc. VERU
Key Stats
- Today's Range
- $2.28 – $2.42
- 50-Day Range
- $2.11 – $7.33
- 52-Week Range
- $2.05 – $7.33
- Volume
- 235K shs
- Average Volume
- 268K shs
- Market Cap
- $37.08 million
- P/E Ratio
- —
- Dividend Yield
- 12.12%
Dividend
- Dividend Yield
- 12.12%
- Annual Dividend
- $0.28
- Payout Ratio
- —
- Ex-Dividend Date
- 2014-04-28
Short Interest
- Short Interest
- 2.26%
- Days to Cover
- 2.78
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Related Stocks
Compare head-to-head: VERU vs LLY·VERU vs JNJ·VERU vs ABBV·VERU vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.